Contribution of Nitric Oxide to Reactive Hyperemia
- 1 July 1998
- journal article
- other
- Published by Wolters Kluwer Health in Hypertension
- Vol. 32 (1) , 9-15
- https://doi.org/10.1161/01.hyp.32.1.9
Abstract
—Our objectives were to (1) test the hypothesis that nitric oxide (NO) contributes to peak reactive hyperemia (RH) in the human peripheral vasculature, (2) examine the impact of atherosclerosis and its risk factors on RH, and (3) investigate whether l -arginine will improve RH in patients with endothelial dysfunction. The endothelium contributes to shear stress–mediated vasomotion by releasing a variety of dilating factors, including NO, but the contribution of NO to peak RH in patients with and without endothelial dysfunction is unknown. Endothelium-dependent and endothelium-independent function was assessed with intrafemoral arterial acetylcholine (ACh) and sodium nitroprusside. RH was produced by occlusion of blood flow to the leg for 3 minutes. The study was repeated after N G -monomethyl- l -arginine (L-NMMA) in 44 subjects and l -arginine in 9 patients with atherosclerosis. There were 15 normal control subjects without risk factors for atherosclerosis and 29 patients with risk factors or angiographic atherosclerosis. Microvascular vasodilation in response to ACh, but not to sodium nitroprusside, was lower in the patients with risk factors or atherosclerosis compared with normal control subjects, P =0.048, and the inhibition of ACh-induced microvascular dilation by L-NMMA was also greater in normal control subjects ( P =0.045). Similarly, RH, including the peak response, was inhibited by L-NMMA in normal control subjects ( P =0.0011) but not in patients with risk factors or atherosclerosis, suggesting that the contribution of NO to both ACh-induced dilation and RH was diminished in patients with risk factors or atherosclerosis. l -Arginine did not affect vasodilation in response to ACh, sodium nitroprusside, or RH. We concluded that (1) NO contributes to all phases of RH in the normal human peripheral vasculature, (2) patients with atherosclerosis or its risks have abnormal NO bioactivity in response to pharmacological and physiological stimulation, and (3) l -arginine does not improve RH in atherosclerosis. Reduced physiological vasodilation in atherosclerosis may contribute to or exacerbate hypertension and ischemia.Keywords
This publication has 34 references indexed in Scilit:
- The vascular effects of L-Arginine in humans. The role of endogenous insulin.Journal of Clinical Investigation, 1997
- Endothelial control of lower limb blood flow in chronic heart failure.Heart, 1996
- Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults.Journal of Clinical Investigation, 1996
- Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis.Journal of Clinical Investigation, 1995
- Effects of infusion of L-arginine into the left anterior descending coronary artery on acetylcholine-induced vasoconstriction of human atheromatous coronary arteriesThe American Journal of Cardiology, 1992
- Effects of L-arginine on forearm vessels and responses to acetylcholine.Hypertension, 1992
- Effects of inhibition of nitric oxide formation on basal vasomotion and endothelium-dependent responses of the coronary arteries in awake dogs.Journal of Clinical Investigation, 1991
- The Role of Nitric Oxide in the Control of Coronary Vascular Tone in Relation to Partial Oxygen Pressure, Perfusion Pressure, and FlowJournal of Cardiovascular Pharmacology, 1991
- Large coronary arteries in humans are responsive to changing blood flow: An endothelium-dependent mechanism that fails in patients with atherosclerosisJournal of the American College of Cardiology, 1990
- Resistance to blood flow at maximal vasodilatation.Hypertension, 1988